Graham J, Earnshaw S, Lim J, Luthra R, Borker R. Cost-effectiveness of afatinib versus erlotinib in the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR Exon 19 deletion mutations. JCP. 2016 May;2(4):31-9.
Michels KB, Rothman KJ. Update on unethical use of placebos in randomised trials. Bioethics. 2003 Apr;17(2):188-204.